From @accpchest.bsky.social 🫁

Female-only models outperformed combined-sex and male-only models in predicting both #COPD incidence and prevalence, which could improve early identification of disease. #HealthDisparities #PulmSky

SMSbiotech Pioneers Inhaled Stem Cell Therapy for COPD with FDA Approval #United_States #Carlsbad #stem_cells #COPD #SMSbiotech

🎧 allergyasthmanetwork.org/podcast/biol...

Produced in partnership with The Itch Podcast.
#Biologics #Asthma #COPD

Dupilumab in #COPD: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use. @atscommunity.bsky.social
doi.org/10.1093/ajrc...

From @accpchest.bsky.social 🫁

Patients with #COPD and #T2DM showed lower lung cancer risk with #SGLT2Inhibitor initiation than with #sulfonylureas medications, particularly men and those with a history of smoking. #PulmSky #EndoSky

Many people with #asthma or #COPD never receive a spacer—or can't afford one. NB Lung has provided 400+ spacers to New Brunswickers in need, helping them breathe easier. ❤️

Your donation helps ensure that cost is never the reason someone struggles to breathe.
Donate: https://tinyurl.com/59x9w3mj

🚀 #ATS2025 buzz check! #COPD, #Asthma & #Pulmonology dominate, with #Data (~21%) & #Efficacy (~18%) driving talk. 82% positive vibes on AI & therapy breakthroughs. 📊🫁 Dive into our full report! http://dlvr.it/TVTFn5 #SocialListening #LucidQuest #ATS25 @atscommunity @ATS_AII

Ontario Health wants to hear from people with #Bronchiectasis, #COPD, or #CysticFibrosis who have used airway clearance devices (e.g., Aerobika, Acapella, Flutter). Take the survey: redcap.link/ic981auw. Caregivers are also welcome to participate.

BBC Expert Proposes Breathing Technique as Non-Medication Aid for COPD Patients

🤖 IA: It's not clickbait ✅
👥 Users: It's not clickbait ✅

#copd #breathing #nhs

👇👇👇

AstraZeneca has announced full results from the Phase III OBERON and TITANIA trials evaluating tozorakimab, an investigational biologic, in adults living with COPD. 

#COPD #RespiratoryHealth #ClinicalTrials #LungHealth #PatientAdvocacy

Study results: AstraZeneca drug holds promise in #COPD.

The trial showed that #tozorakimab cut moderate-to-severe exacerbations significantly in former smokers, the trials’ primary population, compared with placebo.

Discover more: www.emjreviews.com/emj-gold/new...

Is lung aging in COPD reversible? In a #JTD interview at #ERS2026, Prof. Rucheng Chen spoke with Prof. Peter Barnes (Imperial College) on this topic. In vitro, targeting senescence pathways may restore lung cell proliferation—even from long-standing COPD🫁🧬 #Pulmonology #LungAging #COPD

@astrazeneca.com's drug scores two late-stage trial wins as full data boosts blockbuster hopes

#LungDisease #COPD

www.cnbc.com/2026/09/08/a...

A study found semaglutide was associated with nearly 40 percent fewer asthma attacks and 20 percent fewer COPD flare-ups, while three other GLP-1 drugs showed no such association.
youtu.be/X-mMZk2gSqI

#Semaglutide #Ozempic #Wegovy #GLP1 #GLP1Drugs #Asthma #COPD #LungHealth #RespiratoryHealth

Two international #ClinicalTrials found that the investigational #BiologicTherapy #tozorakimab significantly reduced #COPD flare-ups in patients receiving standard treatment.
#LungDisease

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more news.. statnews.com/pharmalot/20... #pharma #FDA #COPD #tariffs #HIV #weight #obesity #Lilly #AstraZeneca #SouthAfrica

ICYMI: AstraZeneca's new COPD drug works where others can't #AstraZeneca #COPD

The #FDA has started a #priorityreview of #AstraZeneca's IL-33-targeting antibody #tozorakimab for chronic obstructive pulmonary disease (#COPD), setting up a decision on the would-be blockbuster in the first quarter of 2027.

pharmaphorum.com/news/fda-sta...

😆 Deliberate #laughter therapy offers an effective low-cost complementary treatment to help patients with #COPD reduce #breathing difficulties at home without specialist support, new research presented at the @europeanrespsoc.bsky.social's #ERSCongress finds.

Presented by our Editorial Review Board member Guilherme Rodrigues at #ERSCongress2026, this poster explored inhaled therapy changes following COPD exacerbations in primary care.

Check it out👇

#COPD #RespiratoryResearch #PrimaryCare #ERSCongress2026